LONDON – Astrazeneca plc is broadening its antibody-drug conjugate (ADC) relationship with Daiichi Sankyo Co. Ltd. in a potential $6 billion development and commercialization deal.
Chinese biotech startup Lynk Pharmaceuticals Co. Ltd., of Hangzhou, has in-licensed global rights from Kobe University and Riken Research Institute in Japan to develop renin-angiotensin system (RAS) inhibitors, which have a novel mechanism of action that can increase chances of developing anti-RAS cancer drugs.
BEIJING – U.S.-Taiwan biotech Acepodia Inc., of Burlingame, Calif., and Taipei, has licensed out two of its cell therapy candidates, ACE-1702 and ACE-1655, to Chinese CAR T therapy developer JW Therapeutics (Shanghai) Co. Ltd.
The two-year standstill provision in Assembly Biosciences Inc.’s potential $540 million pact with Beigene Ltd. to advance hepatitis B virus (HBV) therapies was “highly negotiated,” said Jason Okazaki, Assembly’s chief legal and business officer.
HONG KONG – Takeda Pharmaceuticals Inc. is gaining access to the “library of libraries,” inking an agreement with Twist Bioscience Corp. in one of the Osaka, Japan-based firm’s recent efforts to build a sustained innovative R&D growth engine.
HONG KONG – Zai Lab Ltd. inked a deal to develop and commercialize Turning Point Therapeutics Inc.’s lead drug candidate, repotrectinib, in the greater China markets.
HONG KONG – Tokyo-headquartered Fujifilm Holdings Corp. will increase production of Avigan on the back of a partnership with India’s Dr. Reddy’s Laboratories Inc. and Dubai-based Global Response Aid.
BEIJING – Besides advancing its neutralizing antibodies for COVID-19, Shanghai Junshi Biosciences Co. Ltd. is aiming to expand its pipeline. On July 13, it entered a collaboration with Revitope Oncology Inc.
Carmine Therapeutics Inc. said Tuesday that Takeda Pharmaceutical Co. Ltd. has engaged it in a research collaboration aimed at the discovery, development and commercialization of new nonviral gene therapies for two rare disease targets.
CSL Behring has licensed global rights to Uniqure NV's late-stage hemophilia B gene therapy candidate, AMT-061, for $450 million up front, plus up to $1.6 billion in potential milestone payments and royalties. Uniqure positioned the deal as a boon for its broader gene therapies pipeline, anchored by a Huntington's disease (HD) program. But the move appeared to sour investors hoping for a rumored near-term M&A takeout, sending company shares (NASDAQ:QURE) falling 21.8% to $49.22 on June 25.
RSS
